Investors in Zealand Pharma, the Copenhagen‑based developer of the experimental obesity drug survodutide, were met with disappointment on Thursday when the company disclosed that 18 percent of participants in its late‑stage trial discontinued treatment because of gastrointestinal side effects. The news pushed the stock down as much as 13 percent, echoing a similar slide in June when earlier trial data revealed a quarter of patients had withdrawn.
Trial details and patient experience
The phase‑III study, conducted in partnership with Boehringer Ingelheim, enrolled patients with obesity and pre‑diabetes. Researchers reported that most dropouts occurred during dose‑escalation periods, when doctors had limited ability to adjust dosing in response to emerging side effects. While the drug succeeded in lowering average blood‑sugar levels by up to 1.21 percentage points from a baseline of 7.4 percent, and showed improvements in waist circumference and insulin sensitivity, the high attrition rate raised concerns about tolerability.
Market reaction
Following the release, Zealand Pharma’s shares fell to the bottom of Europe’s benchmark STOXX 600 index as of 1105 GMT. Analysts highlighted the dropout figure as a key risk factor for the company’s commercial prospects, noting that patient adherence is critical for any obesity therapy seeking regulatory approval and market adoption.
Analyst perspective
Equity analysts covering the firm said the data underscored the challenge of balancing efficacy with tolerability in the competitive obesity‑treatment space. “The efficacy signals are encouraging, but a nearly one‑in‑five discontinuation rate due to gastrointestinal issues is a red flag for investors,” one analyst commented. “If the company cannot mitigate these side effects, it may struggle to achieve the market share needed to justify the development costs.”
Regulatory outlook
Regulators in the United States and Europe will scrutinize both the efficacy and safety profile of survodutide before granting approval. The drug’s ability to reduce blood‑sugar and improve metabolic markers could position it as a valuable option for patients with obesity‑related diabetes, but the safety concerns highlighted by the trial will likely prompt additional data requests.
Next steps for Zealand Pharma
Zealand Pharma indicated that it will continue to monitor the trial’s safety data and explore formulation or dosing adjustments aimed at reducing gastrointestinal discomfort. The company also plans to present the full trial results at an upcoming medical conference, where it hopes to provide a more detailed safety analysis and address investor questions.
Broader industry context
The obesity‑treatment market has seen a surge of interest from both biotech firms and large pharmaceutical companies, driven by rising rates of obesity and related metabolic disorders. While several new agents have entered the pipeline, many face similar hurdles of balancing weight‑loss efficacy with tolerable side‑effect profiles. Zealand’s experience reflects a broader industry challenge: delivering a drug that patients can stay on long enough to see meaningful health benefits.
Conclusion
While survodutide shows promise in improving key metabolic markers, the 18 percent dropout rate due to gastrointestinal side effects remains a significant obstacle. Investors and regulators will be watching closely as Zealand Pharma works to refine the therapy and demonstrate that the benefits outweigh the risks.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
